Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered Into the ICM of Adults With FTD and Mutations in the GRN or C9ORF72 Genes

NCT04747431 is registered in ClinicalTrials.gov with Passage Bio, Inc. as lead sponsor.

NCT NCT04747431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04747431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered Into the ICM of Adults With FTD and Mutations in the GRN or C9ORF72 Genes
Lead sponsor
Passage Bio, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 14, 2021
Completion date
August 31, 2031
Enrollment
30 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

c9orf72, dementia frontotemporal, frontotemporal dementia, ftd, ftd-grn